Bookmark
Forward
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.
Chen Wang, Kathy L McGraw, Amy F McLemore, Rami Komrokji, Ashley A Basiorka, Najla Al Ali, Jeffrey E Lancet, Eric Padron, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Alan F List, David A Sallman
Haematologica 2022 Mar 01Sizes of these terms reflect their relevance to your search.
No abstract available.
Citation
Chen Wang, Kathy L McGraw, Amy F McLemore, Rami Komrokji, Ashley A Basiorka, Najla Al Ali, Jeffrey E Lancet, Eric Padron, Olivier Kosmider, Michaela Fontenay, Pierre Fenaux, Alan F List, David A Sallman. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. 2022 Mar 01;107(3):737-739
Mesh Tags
Substances
PMID: 34320786
View Full Text
